New Assisted Treatment for Breast Cancer: Comprehensive Analysis of Therapy
In the area of breast cancer treatment, new assisted treatment has become an important means of treatment. This paper will provide a detailed analysis of the efficacy assessment methodology for new assisted treatment for breast cancer. 1. Newly assisted treatment is defined as full-body treatment before the operation, including, inter alia, chemotherapy, endocrine treatment and target-oriented treatment. The aim is to reduce tumours, reduce the difficulty of surgery and improve the survival and quality of life of patients. 1. Image assessment: observation of tumour size, morphology and tumour changes through video screenings such as mammography X-rays, ultrasound, MRI etc. After treatment, if the tumor is significantly reduced and the morphology changes, the new assisted treatment is effective. 2. Pathological assessment: Pathological examination of tumour cells through tumour tissues subject to surgical removal, and observation of the degree of tumour cell fragmentation, increased activity and the existence of necrosis. After new assisted treatment, pathological examinations can assess the extent of tumour cell degradation and whether there has been a change in drug sensitivity. 3. Assessment of clinical efficacy: Assessment of the effectiveness of new assisted treatment based on indicators such as patient ‘ s clinical performance, lifetime, relapse rate, etc. If the patient ‘ s post-treatment condition is stable, the duration of life is extended and the rate of relapse is reduced, this indicates good clinical efficacy of the new assisted treatment. 1. Integrated assessment: integrated assessment, taking into account multiple data on imaging, pathology and clinical efficacy. If all indicators show that treatment is effective, new assisted treatment can be considered to have a good effect. 2. Individualized treatment: a personalized treatment programme tailored to the specific situation of the patient. In the course of treatment, the patient ‘ s condition changes closely and the treatment programme is adjusted in a timely manner to improve its effectiveness. 3. Long-term follow-up: Long-term follow-up visits to patients following new assisted treatment to assess the long-term effects of treatment, for example, in terms of the quality of their survival, relapse rates and long-term transfer. In general, new assisted treatment for breast cancer is an effective treatment that can be judged by a comprehensive assessment of multiple data, such as image, pathology and clinical efficacy. In the course of treatment, individualized treatment programmes need to be developed and followed up on a long-term basis to obtain better treatment and quality of life.
